Melanoma: mRNA Vaccine Trial Shows Significant Efficacy

A personalized mRNA vaccine designed to target melanoma lowered the risk of death or tumor recurrence by 42 percent when paired with standard care, according to late-stage trial results released by Moderna and Merck on Thursday. The data marks a significant milestone in the development of individualized cancer treatments. The companies have begun discussions with regulatory authorities to pursue approval for the therapy.

The trial involved 1,137 patients diagnosed with stage IIB, IV melanoma, all of whom had undergone surgical removal of their tumors prior to enrollment. Participants were randomized at a 2-to-1 ratio to receive either a combination therapy consisting of the personalized mRNA vaccine alongside Merck’s monoclonal antibody drug Keytruda, or to receive Keytruda alone. The 42 percent reduction in risk compares the outcomes of those receiving the combination treatment against those receiving the standard treatment.

The results were slated for presentation on Saturday at the European Society of Medical Oncology conference in Madrid. However, the release of the top-line figures was accelerated after an oncology news outlet reported the findings prematurely, breaking the planned embargo. The complete dataset regarding the trial has been accepted for publication in the New England Journal of Medicine.

The announcement follows an August report from Moderna and Merck confirming that the vaccine had met its primary goals in the trial. At that time, specific details were withheld pending a formal presentation at the medical conference. The release of the full data provides the first public look at the specific efficacy metrics of the combination therapy.

In a statement accompanying the release, Moderna CEO Stéphane Bancel addressed the potential of the technology to alter the landscape of oncology. “From the beginning, we believed mRNA technology could make it possible to develop cancer treatments uniquely matched to each patient's tumor,” Bancel said. He characterized the trial results as a “defining moment for that vision,” adding that the data “reinforce our conviction that mRNA has the potential to fundamentally change how we treat cancer.”

The development represents a significant step forward in the treatment of melanoma, which remains the deadliest form of skin cancer. Beyond the specific application to melanoma, the outcome supports the broader hypothesis that mRNA vaccines can be repurposed for oncology. The trial's success suggests that individualized cancer-targeting medicines could offer a new paradigm for therapies, moving away from one-size-fits-all approaches toward regimens tailored to a specific patient's tumor profile.

Regulatory authorities are now reviewing the application data as the companies seek to bring the vaccine to market. The full study results are scheduled to be published in the New England Journal of Medicine following the presentation at the Madrid conference. The trajectory of this treatment suggests that mRNA technology, previously associated with infectious disease prevention, is establishing itself as a viable platform for complex, personalized cancer interventions.

The combination of the personalized vaccine with Keytruda demonstrated a clear advantage over the standard-of-care monotherapy in the study population. As the data moves toward publication and regulatory review, the focus shifts to the potential approval of a therapy that aims to prevent melanoma recurrence in patients who have undergone surgery.